# NEKTAR THERAPEUTICS (NKTR) FY2026 Q2 P&L / Income Statement

- Company: NEKTAR THERAPEUTICS (NKTR)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-14, accession number 0001193125-26-349805
- Page: https://plicit.ai/financials/nktr/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/nktr-fy2026-q2-income-statement-sankey.png

## Chart details

Income statement for 2026-04-01 through 2026-06-30. Consolidated revenue, costs and expenses.

- **Total revenue**: 10,131,000 US dollars
- **Total operating costs and expenses**: 52,472,000 US dollars
- **Loss from operations**: negative 42,341,000 US dollars
- **Total non-operating income (expense), net**: 2,040,000 US dollars
- **Loss before provision (benefit) for income taxes and equity method investment**: negative 40,301,000 US dollars
- **Provision (benefit) for income taxes**: 2,000 US dollars
- **Net loss**: negative 40,622,000 US dollars
- **Undisclosed sources**: 10,131,000 US dollars. The filing reports revenue as one line and discloses no sources of it.
- **Research and development (including $1,137 and $613 for the three months ended June 30, 2026 and 2025, respectively, from a related party; and $2,845 and $821 for the six months ended June 30, 2026 and 2025, respectively, from a related party)**: 39,129,000 US dollars
- **General and administrative**: 12,765,000 US dollars
- **Restructuring and impairment**: 578,000 US dollars
- **Loss from equity method investment**: negative 319,000 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.